U.S. Healthcare Services Stock News

NYSE:TOST
NYSE:TOSTDiversified Financial

Toast (TOST) Stock Looks Fair On Fair Value But Rich On Earnings

Toast stock has delivered a 58.9% gain over the past three years, yet on current checks it screens as expensive, with an Excess Returns intrinsic value estimate that sits close to the market price while traditional earnings multiples lean toward an overvaluation signal. Recent shorter term share price weakness and a low overall value score add to the question of whether the current price leaves much room for error. Toast has returned 58.9% over three years, which suggests long term holders...
NasdaqGS:SAIA
NasdaqGS:SAIATransportation

Does Saia (SAIA) Look Expensive Given Its Fair Value Gap?

Saia stock has delivered a 45.2% gain over the past five years, yet both the intrinsic value estimate using a Discounted Cash Flow (DCF) approach and market multiples currently point to the shares trading at a premium. Over the last five years, Saia has returned 45.2%, which means long term holders have already seen a meaningful payoff from the story so far. Strong recent operating execution and record revenue may support expectations for future cash flows, while a sizeable investment plan...
NYSE:CNK
NYSE:CNKEntertainment

Cinemark (CNK) Stock Looks Cheap On Its 140% Five Year Run

Cinemark Holdings has delivered a 140.1% total return over the past five years, yet its valuation signals are pulling in different directions, with an intrinsic value estimate based on a Discounted Cash Flow (DCF) suggesting the stock trades at a discount while earnings based multiples look less forgiving. Over five years, a 140.1% return points to a stock that has already rewarded long term holders and may now draw closer scrutiny on price paid versus future cash flows. Recent record...
NYSE:LMND
NYSE:LMNDInsurance

Lemonade (LMND) Stock Gains Traction As Losses Tighten And Cash Flow Improves

Lemonade came into this earnings print with a bruised stock that had fallen about 25% over the past month, yet shares ticked higher by roughly 3% on the day. That move reflects one thing above all: investors saw a company still posting losses but tightening the screws on profitability. The headline from Q2 is the squeeze on those losses. Net income excluding extra items was a loss of US$43.4m and basic earnings per share came in at a loss of US$0.56. Against that, revenue of US$294.4m and a...
NasdaqCM:MBIN
NasdaqCM:MBINDiversified Financial

Merchants Bancorp (MBIN) Earnings Beat Keeps Valuation In Focus But Is The Upside Still There

Merchants Bancorp (MBIN) drew fresh attention on 29 July 2026 after reporting second quarter 2026 earnings that exceeded Wall Street expectations, supported by loan servicing and asset management fees and higher net interest income. See our latest analysis for Merchants Bancorp. At a share price of $55.51, Merchants Bancorp has delivered a 67.30% year to date share price return and a 91.48% total shareholder return over the past year, suggesting momentum has been building around the company...
NasdaqCM:OTLK
NasdaqCM:OTLKBiotechs

Is Outlook Therapeutics (OTLK) Fully Valued As FDA Approval Reshapes Its Prospects?

Outlook Therapeutics (OTLK) has just secured U.S. Food and Drug Administration approval for LYTENAVA, the first ophthalmic bevacizumab cleared for neovascular age-related macular degeneration in the United States. This development reshapes the company’s investment story. See our latest analysis for Outlook Therapeutics. At a share price of US$1.04, Outlook Therapeutics has seen a 90 day share price return of almost 3x, even after the 30 day share price return fell 34.59% and the 1 year total...
NYSE:ORC
NYSE:ORCMortgage REITs

Orchid Island Capital (ORC) Looks Overvalued On Q2 Earnings And Buyback Update

Orchid Island Capital (ORC) has drawn fresh attention after reporting second quarter 2026 results that shifted from a loss to net income of US$89.19 million, along with an update on its long running share repurchase program. See our latest analysis for Orchid Island Capital. At a share price of US$6.63, Orchid Island Capital has seen a 1-day share price return of 1.07%, while the 30-day and year to date share price returns are down 4.88% and 10.04% respectively. However, the 1-year total...